Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cardiol Therapeutics Inc. (T:CRDL)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Company Contact
Address: Fengate Building
2275 Upper Middle Rd E Suite 101
OAKVILLE ON L6H 0C3
Tel: N/A
Website: www.cardiolrx.com
IR: See website
Key People
N/A    
Business Overview
Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Financial Overview
For the nine months ended 30 September 2019, Cardiol Therapeutics Inc revenues was not reported. Net loss increased 56% to C$10.6M. Higher net loss reflects Investor relations and promotions increase from C$153K to C$1.8M (expense), Research and development increase of 100% to C$2.5M (expense), Share-based compensation increase from C$757K to C$1.9M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $84.46M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$13.59M as of Sep 30, 2019
Net annual income (TTM): -$19.70M as of Sep 30, 2019
Free cash flow (TTM): -$17.11M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 25,877,686 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization